Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai launches Lusedra injection

Eisai launches Lusedra injection

18th November 2009

Eisai has launched its latest therapy this week – the Lusedra (fospropofol disodium) injection.

The treatment is designed for use in patients in need of an intravenous sedative-hypnotic agent.

It is to be used by healthcare professionals trained in the administration of general anaesthesias.

Lusedra is a proprietary water-soluble prodrug of propofol that is converted by alkaline phosphatase enzymes in the body after intravenous injection and is to be administered before sedative effects.

The product was approved in December 2008 by the Food and Drug Administration for use in patients undergoing diagnostic or therapeutic procedures.

In other Eisia news, the organisation revealed earlier this month that a trial into its metastatic breast cancer treatment E7389 (eribulin mesylate) achieved its primary endpoint.

As part of the study, 762 patients were administered either eribulin or one treatment of their choice – including single agent chemotherapy, hormonal treatment or biological therapy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.